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ABSTRACT
Introduction: Glucagon-like peptide 1 receptor
agonists (GLP1RAs) are licensed for the treat-
ment of type 2 diabetes (T2D). They have been
shown to be safe (from the cardiovascular (CV)
perspective) and effective (in terms of gly-
caemia, and in some cases, reducing CV events)
in extensive randomised controlled trials
(RCTs). However, there remain concerns
regarding the generalisability of these findings
(to those ineligible for RCT participation) and
about non-CV safety. For effectiveness, popula-
tion-based pharmacoepidemiology studies can
confirm and extend the findings of RCTs find-
ings to broader populations and explore safety,
for which RCTs are not usually powered, in
more detail.
Method: We did a pre-planned and registered
(PROSPERO registration CRD42020165720)
systematic review of population-based studies
investigating GLP1RA effectiveness and safety,
following Meta-analyses Of Observational
Studies in Epidemiology (MOOSE) guidelines.
Results: A total of 22 studies were identified
(including 200,148 participants and
396,457 person-years of follow-up) exploring
exposure to GLP1RA class, exenatide and
liraglutide (the only individual drugs with
treatment effect estimates identified) on mor-
tality, cardiovascular disease (CVD), acute pan-
creatitis (AP), pancreatic cancer (PC), thyroid
cancer (TC), acute renal failure (ARF), diabetic
retinopathy (DR), breast cancer (BC) and
hypoglycaemia. For CV and mortality out-
comes, studies confirmed the associated safety
of these drugs. For liraglutide, point estimate
(PE) range (PER) major adverse cardiovascular
events (MACE) (0.53–0.95) and PER heart failure
(0.34–1.22) were similar in direction to the
beneficial effect observed in RCTs for MACE but
varied widely for heart failure. For safety out-
comes, exposure was not associated with AP
(PER 0.50–1.17), PC (PER 0.40–1.54), BC (PER
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0.90–1.51) or hypoglycaemia (PER 0.59–1.06).
Only one study was identified exploring each of
TC (no evidence of association, hazard ratio
(HR) 1.46, 95% confidence interval (CI)
0.98–2.19), renal outcomes (no evidence of
association, HR 0.77, 95% CI 0.42–1.41) and DR
(no evidence of association, HR 0.67, 95% CI
0.51–0.90).
Conclusion: In T2D, GLP1RAs appear safe from
the CV perspective and (for liraglutide) may
have associated benefit in primary as well as
secondary CVD prevention. For non-CV safety,
GLP1RA exposure was not associated with an
increased risk of AP, PC, BC or hypoglycaemia;
the other outcomes had too few studies to draw
firm conclusions and should be explored
further.
Keywords: Drug safety; Effectiveness; GLP-1
receptor agonists; Type 2 diabetes
Key Summary Points
Glucagon-like peptide 1 receptor agonist
(GLP1RA) are licensed for the treatment of
type 2 diabetes (T2D).
For cardiovascular effectiveness,
population-based pharmacoepidemiology
studies can confirm and extend the
findings of randomised controlled trials
(RCTs) to broader populations not eligible
for trial participation and explore safety,
for which RCTs are not usually powered,
in more detail.
We did a pre-planned and registered,
agnostic systematic review asking: do the
benefits of GLP1Ras in T2D extend to
those ineligible for RCT participation, and
are safety concerns which arose during the
trials (or in post-marketing) detected, in
population-based observational
pharmacoepidemiology studies?
We considered and reported all clinical
event-based outcomes for effectiveness
and safety in studies which met our
inclusion/exclusion criteria.
For cardiovascular (CV) and mortality
outcomes, studies confirmed the
associated safety of these drugs and, for
liraglutide, correlated closely with the
findings from RCTs, which may extend to
primary CV disease prevention.
For safety outcomes, GLP1RA exposure
was not associated with an increased risk
acute pancreatitis, pancreatic cancer,
breast cancer or hypoglycaemia. There
were insufficient studies to draw
conclusions with regards to thyroid
cancer, renal outcomes and diabetic
retinopathy.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13667132.
INTRODUCTION
Glucagon-like peptide 1 receptor agonists
(GLP1RAs) are licensed for the treatment of
type 2 diabetes (T2D). GLP1RAs have been
shown to improve glycaemic control via regu-
lation and restoration of incretin function,
leading to enhancement of glucose-dependent
insulin secretion, slowed gastric emptying, and
reduction of postprandial glucagon secretion
and food intake [1].
The clinical development programmes for
these agents have robustly assessed the efficacy
and preliminary non-cardiovascular (CV) safety
of GLP1RA drugs for use in people with T2D.
Several have subsequently been assessed for CV
safety in large outcome trials, which have yiel-
ded mixed results in terms of effect on cardio-
vascular disease (CVD; liraglutide,
subcutaneously administered semaglutide and
dulaglutide all reduce CVD, lixisenatide,
extended release exenatide and orally adminis-
tered semaglutide do not) although all appear to
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be safe from the CV perspective [2–8]. Never-
theless, it remains unclear whether the CV
benefit (if any) of these medicines extends to
people who were not eligible to participate in
randomised controlled trials (RCTs).
Population-based database studies present
more generalisable data which can help
broaden and expand the findings of RCTs.
Although many population-based studies apply
appropriate study design and statistical meth-
ods for control of confounding, these studies
are at higher risk of confounding and bias than
RCTs because they are not randomised or blin-
ded. For CV effectiveness and safety, they can
confirm and extend the finding of RCTs to more
heterogeneous populations, especially those
ineligible for trial participation. RCTs are not
powered to detect adverse events, thus it often
remains unclear whether safety signals identi-
fied in trials are a true effect or due to chance. As
such, for non-CV safety, large, observational
studies remain an important tool to identify the
risk of harm, and if detected, to identify char-
acteristics of participants that are associated
with risk.
Here we describe the conduct and findings of
a systematic review of population-based, data-
base effectiveness and safety studies of GLP1RAs
in T2D, either as a class or as individual agents.
METHODS
We prospectively registered an impartial sys-
tematic review of population-based, observa-
tional studies examining effectiveness and
safety of GLP1-RA agents in T2D (PROSPERO
registration CRD42020165720, 16 January
2020). We hypothesised that these studies, if
properly conducted, would show similar esti-
mates for effectiveness and safety to those
described in previous literature (Table 1).
We followed Meta-analyses Of Observational
Studies in Epidemiology (MOOSE) guidelines
for reporting the systematic review. In brief, we
employed two search methodologies (maximal
and targeted search) and interrogated the fol-
lowing research databases: Web of Science,
Medline, EMBASE and EMCARE on Ovid, and
CINAHL on EBSCO using the search criteria
listed in the supplementary material (Table S1).
We searched for studies published between
28 November 2006 (date of licensing of exe-
natide) and end of January 2020. We eliminated
duplicates using each study’s unique identifier.
Two reviewers (JT and TC; TC, medically quali-
fied) independently applied the inclusion and
exclusion criteria first to the title and then to
the abstracts of potentially eligible studies
(Table S2). We searched ENCePP, ClinicalTri-
als.gov and the EU clinical trials register as well
as the references of eligible studies to identify
further publications which may not have been
identified in our searches. We only included
English language studies because of resource
limitations.
Each reviewer checked 10% of the other’s
title and abstract screening. If there was less
than 95% agreement we pre-specified that the
entire list would be re-screened. Third party
arbitration of disputes was planned in the event
of less than 95% agreement. There was 100%
agreement on the 10% of included/excluded
studies so this step was not necessary.
The studies eligible for inclusion were scored
for quality (using the Downs and Black Check-
list for Non-Randomised Studies) [9] but we did
not employ a quality score cut-off for inclusion/
exclusion (Table S3). The quality score has been
shown to have good inter-rater reliability [10].
We then extracted study information from
the studies identified using a standardised data
extraction template (Table S4). We included all
reported clinical event outcomes but decided
post hoc not to include the reporting of surro-
gate markers (continuous variables, e.g. gly-
cated haemoglobin (HbA1c)).
All clinical event outcomes were included.
We tabulated the study information, point
estimates and confidence intervals (CIs) (in-
cluding relevant subgroup information) by
outcome, so studies may appear in multiple
tables (Tables S5, S7, S8, S9, S10, S11, S12, S13).
For safety outcomes, where there were more
than three studies exploring an outcome, we
made forest plots for visual comparison.
We chose to describe studies with fewer than
5000 participants as small; 5000–20,000 partic-
ipants as medium-sized; more than 20,000 as
large. CI widths are described qualitatively.
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Table 1 Effectiveness and safety data from RCTs and other sources
Outcome RCT (and other) evidence
CVD MACE (HR) Non-fatal MI (HR) Non-fatal stroke (HR)
Exenatide QW [3]
0.91 (0.83, 1.00) 0.95 (0.84, 1.09) 0.86 (0.70, 1.07)
Liraglutide [6]
0.87 (0.78, 0.97) 0.88 (0.75, 1.03) 0.89 (0.72, 1.11)
Mortality CVD mortality (HR) ACM (HR)
Exenatide QW [3]
0.88 (0.73, 1.05) 0.86 (0.77-0.97)
Liraglutide [6]
0.78 (0.66, 0.96) 0.85 (0.74, 0.97)
Pancreatic outcomes (PC and AP) There has been concern that GLP1RA exposure causes an increased risk of AP and
PC. It is unclear whether this is an actual drug effect because of the small numbers
arising in the clinical trial programmes and because T2D is a risk factor for AP and
PC, in and of itself. Development of AP and PC is increased by diagnosis of DM,
and the prevalence in the studies may be affected by reverse causality (where DM is
caused by the presence of undiagnosed AP or PC). GLP1RAs have been found to
induce chronic pancreatitis in rat models that can progress to cancer, via a suggested
pathway involving ductal metaplasia and increased cell replication [47]
Thyroid cancer Animal models have suggested that GLP1RA exposure may be associated with an
increased risk of MTC [48]
Renal outcomes There are no trials examining microvascular disease and GLP1RAs as a primary
outcome
Recent trial data suggest that liraglutide, dulaglutide, semaglutide and lixisenatide may
delay the onset of diabetic renal disease (through various secondary outcome
measures) [2, 5–8]
Diabetic retinopathy The mechanism by which GLP1RA exposure may influence DR is unclear. It may
relate to rapid correction of hyperglycaemia, as has previously been reported with
insulin [49] or may be related to the GLP1RA exposure itself
CVOT data suggest that semaglutide (subcutaneously administered) increased the
incidence of DR (HR 1.76, 95% CI 1.11–2.78) but not with orally administered
semaglutide (although those with prevalent DR were excluded) [4, 7]
For liraglutide there was a numerical, but not significant, imbalance towards more DR
following exposure [6]
Dulaglutide appears to reduce DR [2]
Breast cancer A numerical imbalance of incident breast cancer was found in an RCT of liraglutide
[50]. No mechanism has been elucidated for this putative adverse effect although
there was no imbalance of breast cancer in LEADER [6]
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We did not apply meta-analytic methods to
the identified studies because of axiomatic
breaches in principles of meta-analysis (too few
studies exploring a particular outcome, signifi-
cant diversity in study design, confounder
adjustment and analysis methods, multiple
effectiveness estimates derived from same data
source giving rise to possible double counting,
and studies examining different GLP1RA
agents; these breaches either rendered the
effectiveness estimates uncombinable or would
lead to a false illusion of precision) [11]. In
addition there were too few studies for each
outcome to provide funnel plots to assess the
risk of publication bias (Cochrane Library rec-
ommends more than 10 studies) [12]. Thus we
present a narrative systematic review.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
RESULTS
Figure 1 shows a flow diagram of the studies
included at each stage of applying our inclusion
and exclusion criteria. The search results and
the reviewers’ inclusion and exclusion decisions
are available on request. We present a synopsis
of each study by outcome in Tables 2, 3, 4, 5, 6,
7, 8 and 9. Further information on the included
studies are presented in Tables S5, S7, S8, S9,
S10, S11, S12 and S13.
We found 22 studies in total of which 12
were commercially funded [13–25] and 10 were
funded by academic/non-profit/government
organisations [26–35]. Six studies were identi-
fied through reference searching. The total
number of participants in the studies was
200,148 with follow-up of 396,457 person years
(PYs).
Table S3 reports the quality score agreed by
two independent reviewers (TC and JT). The
Table 1 continued
Outcome RCT (and other) evidence
Hypoglycaemia GLP1RA agents, either as a class or individually, do not appear to be associated with
an increased risk of severe hypoglycaemia. In the LEADER trial, liraglutide exposure
was association with less hypoglycaemia than placebo (2.4% vs. 3.3%) [6]
ACM all-cause mortality, AP acute pancreatitis, CVD cardiovascular disease, CVOT cardiovascular outcome trial, DM
diabetes mellitus, DR diabetic retinopathy, GLP1RA glucagon-like peptide 1 receptor agonist, HR hazard ratio, LEADER
Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results, MACE major adverse cardio-
vascular events, MI myocardial infarction, MTC medullary thyroid cancer, PC pancreatic cancer, QW once weekly, RCT
randomised controlled trial, T2D type 2 diabetes
Fig. 1 PRISMA diagram
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Table 2 Cardiovascular disease
Exposure Study synopsis
GLP1RA class
2.1 A small 2016 American cohort study examined patients exposed to GLP1RA class agents (100% on background
metformin) versus insulin, SUs and DPP4Is head-to-head on CVD (composite of MI, UA, stroke and
coronary revascularisation) [32]. A neutral association with CV events was observed comparing GLP1RAs
head-to-head to insulin, SUs or DPP4Is, consistent according to baseline HbA1c (Tables S5.4 and S6). The
CIs overall were narrow. This associated signal of neutral effect remained consistent in subgroup analysis (on-
treatment and primary/secondary CVD prevention)
2.2 A small 2018 British cohort study assessed the effect of adding a GLP1RA class agent or an OAD to those
already taking insulin and overweight on MACE, its components, a composite of the non-fatal MACE
components and HF [26]. For MACE, there was an associated reduction for the GLP1RA class overall with
narrow CIs (Table S5.5), with a reduced association also described for liraglutide, but no association for
exenatide. CIs for the individual agents were wider than for the class overall. For the composite of the non-
fatal components of MACE, there was no association for both the class and the individual agents, but with
wide CIs (primary CVD prevention only). For the composite component of stroke, there no association for
exenatide, liraglutide or for the class but with wide CIs in all three comparisons. For the MI composite
component, there was no association in all three comparisons but with wide CIs. For HF, there was no
association for all three comparisons, again with wide CIs (primary CVD prevention only). These associations
were independent of baseline HbA1c (DNS). The associated reduction in MACE was driven by a reduction
in ACM for the class overall and for the individual agents (Table S7.3)
2.3 A medium-sized 2017 British open cohort study explored GLP1RA class exposure vs. non-exposure (similar to
OAD) [34]. As a secondary outcome (primary outcome was ACM, Table S7.1), in a population at low-risk of
CVD, GLP1RA class exposure revealed a neutral association on incident CVD (Table S5.7). The CIs were
narrow
Exenatide
2.4 A large 2011 American cohort study examined the effectiveness of exenatide BD exposure on incident CVD
composite (MI, ischaemic stroke or coronary revascularisation) and CVD-related hospitalisation compared to
no exenatide exposure in those already on other antihyperglycaemic drugs and without a CVD history in the
preceding 9 months [13]. There was an associated reduction in the HR with exenatide exposure compared to
no exposure in the PS-weighted, PS-stratified and the ITT analyses for CVD composite and for
hospitalisation for CVD events. The CIs were all narrow. Authors observed lipid levels, BP, obesity and
evidence of prior CVD were greater in those exposed to exenatide than those who were not, thus the
exenatide-exposed would be at elevated baseline risk of CVD, lending support to exenatide being associated
with a reduction in CVD (Table S5.1)
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scores ranged from 12 to 22 (the maximum
achievable score would have been 29/31 as
none of the studies was randomised). None of
the study designs as described appeared to have
been affected by immortal time bias arising
from an inappropriate start date to follow-up.
The only individual agents investigated were
exenatide or liraglutide, other agents were
included in GLP1RA class studies but without
information being provided on individual agent
effectiveness or safety estimates.
Cardiovascular Disease
GLP1RA class: three studies explored the effect
of the GLP1RA class overall on CVD with two
finding no association and one finding an
associated reduction in major adverse cardio-
vascular event (MACE) [26, 32, 34]. Specifically,
when compared to other antihyperglycaemic
agent (AHAs, including injectable therapies)
head-to-head, one study (where the class com-
prised 72% exenatide, 29% liraglutide; 9–13%
had established CVD, and 100% were on
Table 2 continued
Exposure Study synopsis
2.5 A medium-sized 2015 American cohort study compared the risk of CV outcomes in people exposed to
exenatide BD versus insulin [33]. In the whole population, exenatide exposure was associated with a reduced
risk of HHF, stroke and a composite of MI/stroke but not for MI alone, where there was no association
(Table S5.2). The CIs were narrow for the MI and stroke composite and for HF, but wider for the individual
composite components. Subgroup analyses in those without pre-existing CVD and without pre-existing CVD
or CKD reported the same findings as the main analysis but also reported an associated reduction in MI for
both. Those with higher baseline HbA1c had an associated greater reduction in HHF and MI or stroke with
exenatide exposure than the unexposed (DNS)
2.6 A small 2015 American cohort study investigated primary prevention for time-to-first-HHF and all-cause
hospitalisation for those exposed to exenatide versus those on OADs [35]. Exenatide exposure was associated
no effect in all-cause hospitalisation, with wide CIs (Table S5.3), but there were insufficient cases to allow for
assessment of HHF (DNS)
Liraglutide
2.7 A medium-sized 2019 Scandinavian cohort study (100% on background metformin) compared liraglutide vs.
DPP4I exposure on MACE [23]. Liraglutide was associated with a reduction in MACE (narrow CIs). This
was driven by an associated reduction in the CV death composite component but not for MI or stroke. There
was no association for HF and also for an expanded CV composite (MACE, other IHD, coronary
revascularisation and PAD). The reduced association for MACE was greater for the secondary CVD
prevention subgroup than the population overall, but attenuated to a neutral association in the primary
prevention subgroup when analysed separately (Table S5.6). Subgroup analysis suggests a greater associated
benefit in women, those C 65 years old and those on baseline insulin (DNS). For MACE, the associations
remained stable in sensitivity analysis (on-treatment, additionally adjusted and imputed missing data, DNS)
ACM all-cause mortality, BD twice daily, BP blood pressure, CI confidence interval, CKD chronic kidney disease, CVD
cardiovascular disease, DNS data not shown, DPP4I dipeptidyl peptidase 4 inhibitor, GLP1RA glucagon-like peptide 1
receptor agonist, HbA1c glucated haemoglobin, HF heart failure, HHF hospitalised heart failure, IHD ischaemic heart
disease, ITT intention-to-treat, MACE major adverse cardiovascular events, MI myocardial infarction, OAD oral antidia-
betic drug, PAD peripheral artery disease, PS propensity score, SU sulfonylurea, UA unstable angina
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background metformin) showed no association
for MACE (and its components; Tables 2.1, S5.4,
S6), irrespective of baseline HbA1c and consis-
tent in subgroup analysis [32]. Versus oral
antidiabetic drug (OADs, excluding
injectable therapies) (in those already exposed
to insulin and overweight; exenatide 72%,
liraglutide 28%, 100% background insulin, 20%
baseline CVD; Tables 2.2 and S5.5), another
study showed an associated reduction in MACE
(driven by a mortality reduction). In the same
study, for a composite of non-fatal MACE
components and for hospitalised heart failure
(HHF) (primary CVD prevention only) there was
no association [26]. Another study of a popula-
tion at low risk of CVD suggested that GLP1RA
exposure was associated with no effect on inci-
dent CVD compared to people not exposed




3.1 A medium-sized 2017 British open cohort study explored the effects of GLP1RA class exposure vs. non-
exposure on ACM [34]. Exposure was associated with reduced IRRs for ACM; subgroup analysis by agent also
showed reduced associations for both liraglutide and exenatide when analysed separately. GLP1RA class
association remained in the low risk of CVD subgroup (Table S7.1). All CIs were narrow. Subgroup analysis
further suggests that the association for reduced ACM remained stable irrespective of baseline BMI, CVD and
BP, but there was a greater associated benefit in those with more DM complications and also with increasing
age (DNS)
3.2 A small 2016 American cohort study (100% on background metformin) explored ACM in those exposed to the
GLP1RA class vs. insulin, SUs and DPP4Is head-to-head [32]. There was a neutral association with ACM in
all three pairwise comparisons, but the CIs were wide (Tables S6 and S7.5)
3.3 A small 2018 British cohort study examined liraglutide or exenatide plus insulin vs. OAD plus insulin’s effect on
ACM (100% on insulin) [26]. This showed an associated reduction in ACM with liraglutide, exenatide and
the GLP1RA class exposure (Table S7.3), independently of HbA1c reduction (DNS). The CIs were wide,
wider still for the individual drug comparisons. The associated rate of ACM remained lower following
adjustment for age, duration of DM, insulin use, gender, socioeconomic status, alcohol use, eGFR, lipid profile
and hypoglycaemia (DNS)
Exenatide
3.4 A small 2015 American cohort study explored the effect of exenatide exposure vs. non-exposure on ACM [35].
There was no association in ACM with exenatide exposure, but with very wide CIs (Table S7.2). There was
no associated difference in CVD or HF mortality between the groups (DNS)
Liraglutide
3.5 A large 2019 Scandinavian cohort study (100% on background metformin) explored liraglutide exposure’s effect
on ACM and CV mortality vs. DPP4I [23]. This study showed an associated reduction in both ACM and
CV death in those exposed to liraglutide (Table S7.4). The CIs were narrow
ACM all-cause mortality, BMI body mass index, BP blood pressure, CI confidence interval, DM diabetes mellitus, DNS data
not shown, DPP4I dipeptidyl peptidase 4 inhibitor, eGFR estimated glomerular filtration rate, GLP1RA glucagon-like
peptide 1 receptor agonist, HbA1c glucated haemoglobin, HF heart failure, IRR incidence rate ratio, OAD oral antidiabetic
drug, SU sulfonylurea
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Table 4 Pancreatic outcomes
Exposure Study synopsis
Exenatide
4.1 A large 2010 American cohort study assessed the risk of AP in those exposed to exenatide BD compared to
those not exposed to incretin therapy and also to people without DM [28]. All participants did not have
claims for AP in the preceding 6 months. The CIs were wide. Although a diagnosis of DM was associated
with an increased risk for AP, compared to OADs, exenatide exposure was associated with a neutral effect on
AP (Table S8.1)
4.2 A large 2011 American cohort study explored the association of exenatide BD vs. those using OAD with AP
(using an adjudicated definition) in people without prior pancreatic disease [15]. There was a reduced
association in the PS-adjusted analysis with current use of exenatide; a neutral association with recent use of
exenatide compared to OAD; and an increased association with past exenatide use. All of the CIs were wide.
The nested (within cohort) case–control study showed the same effect for the current use (DNS) and recent
use (DNS), but for past use it showed a neutral association (Table S8.2)
4.3 A large 2010 American cohort study explored the association of exenatide BD initiation on time-to-first-AP vs.
OAD [25]. There was a neutral association for AP with exenatide in the main IPTW analysis, and also in the
crude, ITT and PS-stratified analysis (Table S8.3). Current and recent exenatide exposure also showed a
neutral association, whereas past exposure showed a reduced association for AP. The CIs were narrow for
current and past exposure, but wide for recent exposure
4.4 A large 2012 American cohort study explored the association of exenatide BD vs. non-users on AP and PC [22].
Furthermore, a quasi-randomised sensitivity analysis using out-of-pocket expenses was also undertaken. The
logistic regression and quasi-randomised analyses showed a neutral association of exenatide with both AP and
PC (Table S8.4). The CIs for AP were narrow, as was the CI in the quasi-randomised PC analysis; CIs were
wide in the main cohort PC analysis
4.5 A small 2014 American SCCS study explored exenatide BD use (controlling for time-invariant confounders) on
AP [30]. The study found that exenatide exposure was associated with a neutral effect on the IDR of AP in
each time window and in the modified analyses (Table S8.5). The CIs were wide
4.6 A large 2019 American cohort (and nested case–control) study examined PC incidence in patients initiated on
exenatide BD or QW vs. OADs [14, 19]. The study showed no association for exenatide exposure on PC in
the main cohort, the cumulative response and the nested case–control analysis (Table S8.8). The CIs were
wide
Liraglutide
4.7 A 2014 American cohort study compared liraglutide vs. OADs for association with AP and PC (study size not
ascertainable) [18]. Liraglutide exposure was associated with a neutral effect for AP and no association for PC.
This signal was consistent between both the ITT and on-treatment analysis (Table S8.6). All CIs were wide
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Exenatide: we found four studies that repor-
ted a CVD-related outcome for exenatide alone.
Three reported a reduction in CVD associated
with exenatide, and one reported no association
[3, 13, 33, 35].
Compared to OADs: one study showed an
associated reduction with exenatide exposure
for a myocardial infarction (MI), stroke and
coronary revascularisation composite and also
CVD-related hospitalisation (where lipid levels,
Table 4 continued
Exposure Study synopsis
4.8 A medium-sized 2019 American cohort study compared adjudicated AP and PC outcomes from individuals
exposed to liraglutide vs. OAD [16]. ITT and TOD analyses were performed which showed a neutral effect of
liraglutide for AP and PC overall (Table S8.7). For liraglutide, the association for AP and PC remained
neutral in each of the head-to-head drug comparisons (vs. DPP4I, SUs and TZDs) when repeated
individually. CIs were wide
AP acute pancreatitis, BD twice daily, CI confidence interval, DM diabetes mellitus, DPP4I dipeptidyl peptidase 4 inhibitor,
IDR incidence density ratio, IPTW inverse probability of treatment weighting, ITT intention-to-treat, OAD oral antidi-
abetic drug, PC pancreatic cancer, PS propensity score, QW once weekly, SCCS self-controlled case series, SU sulfonylurea,
TOD time-on-drug, TZD thiazolidinedione
Table 5 Thyroid cancer
Exposure Study synopsis
Exenatide
5.1 A large 2019 American cohort (and nested case–control) study of exenatide exposure vs. OAD explored the
association of exenatide with TC [14, 19]. There was no association for TC in the main cohort and the
cumulative response (both with wide CIs) or the nested case–control analysis (with narrower CIs; Table S9.1)
CI confidence interval, OAD oral antidiabetic drug, TC thyroid cancer
Table 6 Renal outcomes
Exposure Study synopsis
Exenatide
6.1 A medium-sized 2012 American cohort study examined the risk of incident ARF associated with exenatide
exposure vs. OADs (excluding sitagliptin) in patients without baseline ARF, ESRD, renal dialysis or renal
transplant (baseline CKD 1.9%) [21]. There was no association in the time-to-renal-failure Kaplan–Meier
analysis for exenatide exposure with ARF (Table S10.1). When the analysis was restricted to patients with
high risk of ARF, when the data was censored at 180 days and when a modified diabetic control group was
used there remained no association of exenatide exposure with ARF (DNS). The CIs were narrow
ARF acute renal failure, CI confidence interval, CKD chronic kidney disease, DNS data not shown, ESRD end-stage renal
disease, OAD oral antidiabetic drug
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obesity and prior CVD rates were higher in the
exenatide-exposed; Tables 2.4 and S5.1) [13].
Another showed no association in all-cause
hospitalisation, but featured insufficient cases
to allow for assessment on HHF (Tables 2.6 and
S5.3) [3, 35].
Table 7 Diabetic retinopathy
Exposure Study synopsis
GLP1RA class
7.1 A medium-sized 2018 British cohort study investigated the association of incident DR (in those without
prevalent DR) in GLP1RA class exposure vs.[ 2 OADs [27]. The study included negative (DPP4I) and
positive (insulin) controls (DNS). Exenatide exposure was associated with a reduced effect on DR in the main
cohort and[ 12 months use; a neutral association at\ 6 months use; and an increased association for
the[ 6 to B 12-month time window (Table S11.1). The CIs were narrow. There was no associated effect
modification by duration of DM treatment and HbA1c levels, but GLP1RA-associated DR was increased
among patients with arterial hypertension and on ACEI (DNS)
ACEI angiotensin-converting enzyme inhibitor, CI confidence interval, DM diabetes mellitus, DNS data not shown, DPP4I
dipeptidyl peptidase 4 inhibitor, DR diabetic retinopathy, GLP1RA glucagon-like peptide 1 receptor agonist, HbA1c glu-
cated haemoglobin, OAD oral antidiabetic drug
Table 8 Breast cancer
Exposure Study synopsis
GLP1RA class
8.1 A small 2016 British cohort study compared those taking GLP1RA class agents vs. DPP4Is on the risk of
incident breast cancer [29]. Detection bias was handled in sensitivity analysis by varying lag time windows,
censoring in situ breast cancer, performing an IPTW analysis and stratifying by mammography screening.
Overall, there was a neutral association of GLP1RA class on breast cancer (and also for exenatide and
liraglutide alone, when analysed separately). The dose–response analysis was associated with a transient
increase in the breast cancer risk of those in the[ 3 to B 4-year exposure window, which attenuated in
longer exposure (Table S12.1). Sensitivity analyses yielded similar results to the primary analysis, except that
those with no mammography screening had an association with increased breast cancer risk (DNS). All of the
CIs were wide
Liraglutide
8.2 A large 2018 American cohort study compared individuals taking liraglutide vs. OADs on the risk of developing
adjudicated incident breast cancer [17]. ITT and cumulative TOD analyses were performed. Detection bias
was handled comparing mammography frequency between the groups. Liraglutide exposure was associated
with a neutral risk of breast cancer in both the ITT (for all comparator agents) and also in the cumulative
TOD analyses (Table S12.2). The CIs were narrow, except the recent TOD which was wide
CI confidence interval, DNS data not shown, DPP4I dipeptidyl peptidase 4 inhibitor, GLP1RA glucagon-like peptide 1
receptor agonist, IPTW inverse probability of treatment weighting, ITT intention-to-treat, OAD oral antidiabetic drug,
TOD time-on-drug
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Compared to insulin (which is known to
increase the risk of CVD [36]), exenatide expo-
sure was associated with a reduction in HHF,
stroke and an MI/stroke composite but not MI
alone (Tables 2.5 and S5.2); there was an asso-
ciated reduction in all outcomes when those
without pre-existing CVD or CVD/chronic kid-
ney disease (CKD) were analysed separately [33].
Those with higher baseline HbA1c had a greater
associated reduction in HHF alone and MI/
stroke composite. A final study for exenatide
showed no association towards reduction in
MACE. For primary CVD prevention only, there
was no association for the non-fatal CVD com-
posite, MI, HHF and stroke (independent of
baseline HbA1c; data not shown (DNS))
(Tables 2.2 and S5.5) [26].
Liraglutide: two studies reported the effect of
liraglutide on CVD [23, 26]. Both showed
reductions in MACE in the population overall
(driven by a mortality reduction), in popula-
tions with less established CVD – 20% [26] and
16% [23] vs. 81% in Liraglutide Effect and
Action in Diabetes: Evaluation of cardiovascular
outcome Results (LEADER) [6] and similar levels
of baseline glycaemic control [23, 26]. Against
dipeptidyl peptidase 4 inhibitors (DPP4i), one
study showed a reduction in MACE overall and
in secondary, but not primary, CVD prevention
(Tables 2.7 and S5.6). Women, those aged
65 years or more, and those on baseline insulin
benefitted most from this associated reduction
in subgroup analysis (DNS) [23]. Versus insulin,
the other study showed an associated reduction
in MACE but no association for MI, stroke, MI/
stroke composite and for HHF, independent of
baseline HbA1c (Tables 2.2 and S5.5; MI/stroke/
HHF explored primary prevention only, DNS)
[26].
Mortality
For GLP1RA class overall (vs. unexposed, i.e.
usual care) exposure was associated with an all-
cause mortality (ACM) reduction irrespective of
baseline body mass index (BMI), CVD status and
BP (Tables 3.1 and S7.1) but a greater associated
benefit in those with more diabetes mellitus
(DM) complications and in older people (DNS)




9.1 A small 2018 American cohort study investigated rates of hypoglycaemic events in those exposed to GLP1RA
class agents (comparing early GLP1RA treatment intensification, delayed or no treatment intensification vs.
insulin) [24]. Treatment intensification (early or delayed) was not associated with a change in risk of
hypoglycaemia compared to insulin (Table S13.2). The CI widths varied depending on comparison
Exenatide
9.2 A small 2017 American cohort study investigated the association of exenatide QW on hypoglycaemia vs. basal
insulin in patients naı̈ve to injectable therapy by ethnicity [31]. Exenatide exposure was associated with a
neutral effect on the rates of hypoglycaemia events in all groups (Table S13.1). CIs were narrow for the white
ethnicity but wide for the other ethnic groups. For background characteristics, see Table S14
9.3 A medium-sized British 2018 cohort study explored the association with severe hypoglycaemia in those
previously naı̈ve to any exenatide therapy vs. basal insulin ± OAD [20]. No association for exenatide on
severe hypoglycaemia was observed, although the absolute rates of hypoglycaemia were higher in the insulin-
exposed group compared to exenatide (DNS). No effect estimates or CIs reported
CI confidence interval, DNS data not shown, GLP1RA glucagon-like peptide 1 receptor agonist, OAD oral antidiabetic
drug, TOD time-on-drug, QW once weekly
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DPP4Is head-to-head, there was no association
with ACM in all comparisons (Tables 3.2 and
S7.5) [32]. Against OADs ? insulin, there was an
associated reduction for ACM (Tables 3.3 and
S7.3) [26].
For exenatide, two studies were associated
with a reduction in ACM [26, 34], and one
showed no association [35]. Versus non-expo-
sure, the associated reduction in ACM was irre-
spective of baseline BMI, CVD status and BP
(Tables 3.1 and S7.1) but a greater associated
benefit was seen in those with more DM com-
plications and in older people (DNS) [34]. Ver-
sus OADs and insulin, there was an associated
reduction in ACM (Tables 3.3 and S7.3) [26].
Finally, versus the unexposed, there was no
association with ACM (Tables 3.4 and S7.2) [35].
For liraglutide, all three studies were associ-
ated with a reduced risk of ACM, two vs. OAD
[26, 34] and one vs. DPP4I [23] (Tables 3.1 [34],
3.3 [26], 3.5 [23], and S7.1 [34], S7.3 [26], S7.4
[23]). In one study there was also an associated
reduction in CV death (Tables 3.5 and S7.4)
[23]. For another, this was irrespective of base-
line BMI, CVD status and BP but a greater
associated benefit was shown in those with
more DM complications and in older people
(DNS) [34].
Pancreatic Outcomes
We found eight studies reporting the associa-
tion of GLP1RAs with pancreatic outcomes,
seven vs. OADs/usual care
[14, 16, 18, 19, 22, 25, 28] and one as an self-
controlled case series (SCCS) [30].
Acute Pancreatitis
We found seven studies that explored acute
pancreatitis (AP) following GLP1RA exposure
[15, 16, 18, 22, 25, 28, 30], five for exenatide
[15, 22, 25, 28, 30] and two for liraglutide
[16, 18] (Fig. 2).
For exenatide, four studies showed no asso-
ciation with AP following exposure (Tables 4.1
[28] and S8.1, 4.3 [25] and S8.3, 4.4 [22] and
S8.4, 4.5 [30] and S8.5); in one study when ‘out-
of-pocket’ expenses were used as a ‘quasi-ran-
domised’ variable, there remained no
association for AP [22]. Another study suggested
an associated reduction in AP (Tables 4.2 and
S8.2) [15]. When time post-exposure was con-
sidered, the same study showed an associated
increase in AP with past exenatide use [15], but a
different study suggested an associated reduc-
tion for past exposure (Tables 4.3 and S8.3) [25].
In the case of an SCCS, although throughout
the study the associated effect of exenatide on
both recurrent (DNS) and incident AP increased
over time following exposure (as did both
bounds of the 95% CIs), the effect estimates did
not reach statistical significance (Tables 4.5 and
S8.5) [30].
For liraglutide, two studies showed no asso-
ciated with AP (Tables 4.7 [16] and S8.6, 4.8 [18]
and S8.7). In one of these studies, there
remained no association for AP in both the
intention-to-treat (ITT) and on-treatment anal-
ysis [18].
Pancreatic Cancer
We found four studies that explored pancreatic
cancer incidence following GLP1RA exposure,
two for exenatide [14, 19, 22] and two for
liraglutide [16, 18] (Fig. 3).
For exenatide, two studies showed no asso-
ciation following exposure (Tables 4.4, S8.4 and
Tables 4.6, S8.8, the latter in the main cohort,
cumulative response and nested case–control
analyses) [14, 19, 22].
For liraglutide, two studies showed no asso-
ciation in all analyses (Tables 4.7 [18] and S8.6,
4.8 [16] and S8.7). In one of these there was no
association for pancreatic cancer (PC) in both
the ITT and on-treatment analysis in the 2014
study [18].
Thyroid Cancer
No study we found explored medullary thyroid
cancer (MTC) (the specific cancer type puta-
tively associated with GLP1RA exposure,
Table 1). The only study identified reported no
association with the risk of TC (which included,
but was not limited to, MTC) with exenatide
exposure, vs. OAD, in the main cohort and the
cumulative dose–response analysis, nor the
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nested case control study (Tables 5.1 and S9.1)
[14, 19].
Renal Outcomes
Only one study described renal outcomes,
which suggests that exenatide exposure (vs.
Fig. 2 Acute pancreatitis forest plot
Fig. 3 Pancreatic cancer forest plot
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sitagliptin) was not associated with an increased
time-to-renal-failure or acute renal failure (ARF),
in which the majority of participants did not
have baseline CKD (Tables 6.1 and S10.1) [21].
Diabetic Retinopathy
The one study we identified showed no associ-
ation of GLP1RA class (vs. more than two OADs)
on diabetic retinopathy (DR) incidence in those
without pre-existing eye disease (Tables 7.1 and
S11.1) [27]. No effect modification was detected
by duration of DM treatment or baseline HbA1c
but there was an increased risk of DR in those




The two studies we identified assessing the
effect of GLP1RA exposure on breast cancer (vs.
DPP4I [29], Tables 8.1 and S12.1 and vs. OAD
[17], Tables 8.2 and S12.2) showed that both the
GLP1RA class overall and the specific agents
liraglutide and exenatide were associated with a
neutral effect on risk of incident breast cancer,
consistent in the duration response and ITT
analyses in both studies overall [17, 29], apart
from an associated transient increased risk at
more than 3.1 years to less than 4 years in one
[29].
Hypoglycaemia
We found three studies exploring rates of severe
hypoglycaemia, two investigating exenatide
exposure (Tables 9.2 [31] and S13.1, and 9.3
[20]) and one the GLP1RA class overall
(Tables 9.1 [24] and S13.2). All studies used an
insulin comparator group (as opposed to OAD)
and showed no association with hypoglycaemia
risk [20, 24, 31].
DISCUSSION
Summary of Key Findings
For context, Table 1 gives a summary of the RCT
(or other source of) evidence for the outcomes
described in this review. Notably, of the indi-
vidual GLP1RA agents, only studies exploring
exenatide and liraglutide were found (because
these have been available longest). Conse-
quently, there is a need to undertake large
observational studies of newer GLP1RA drugs
(dulaglutide, semaglutide and lixisenatide). This
discussion is, consequently, mainly limited to




For the GLP1RA class, studies either showed no
association [32, 34] or an associated reduction
[26] with CVD. These studies appear to confirm
CVD safety for the GLP1RA class overall.
For exenatide, two studies reported an asso-
ciated reduction for CVD [13, 33] and two
studies reported no association [26, 35]. While
these data confirm CVD safety, given that the
cardiovascular outcome trial (CVOT) for exe-
natide did not show a reduction in CVD, exe-
natide should not be prescribed for the purposes
of reducing CVD in people with T2D.
For liraglutide, two studies demonstrated an
associated reduction for CVD [23, 26]. These
findings first confirm CVD safety, but since
liraglutide reduced MACE in the CVOT, they
also confirm and extend these findings to those
living with T2D but with a broader CV risk
profile than those at elevated CV risk included
in the CVOT for enrichment purposes.
Mortality
For the GLP1RA class, two studies showed an
associated reduction in ACM [26, 34] and one
showed no association [32]. No studies explored
CV death.
For exenatide two studies were associated
with a reduction in ACM [26, 34] and another
showed no association [35]. No studies explored
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CV death. EXenatide Study of Cardiovascular
Event Lowering Trial (EXSCEL) showed nomi-
nally significant reduction in ACM (but not for
CV death) [3]; for ACM these studies appear to
suggest that exenatide may be associated with
mortality postponement in a broad population
and certainly does not appear to increase
morality risk.
For liraglutide, all three studies demon-
strated an associated reduction for ACM
[23, 26, 34] and one study also showed a
reduction in CV death [23]. LEADER showed a
reduction in ACM and CV death [6]; for both
these outcomes the studies we found appear to
confirm that liraglutide may be associated with
a postponement of both ACM and CV death in
these broad populations.
Safety
The current regulatory position for GLP1RA
safety is as follows. The European Medicines
Agency (EMA) has issued a class-wide warning
for AP [37] and specifically for semaglutide, for
worsening of DR [38]. For semaglutide only, the
US Food and Drug Administration (FDA) warns
of worsening of DR, particularly in those
already treated with insulin [39]. The FDA has
issued class-wide warnings for AP and PC [40],
for MTC [39], for ARF [39] and recently for
hypoglycaemia in the context of co-prescription
with Sus [39]. The Medicines and Healthcare
products Regulatory Agency (MHRA) has
recently warned about diabetic ketoacidosis
(DKA) in the context of rapid insulin dose-re-
duction following GLP1RA initiation [41]. Not
all of the agents/outcomes are addressed by
studies included in this review.
Acute Pancreatitis
Seven studies explored this outcome
[15, 16, 18, 22, 25, 28, 30]. For exenatide, four
studies suggest no association [22, 25, 28, 30]
and one an associated reduction [15]. For
liraglutide all studies reported no association
[16, 18]. In summary, the studies we found do
not suggest that GLP1RAs (as a class or indi-
vidual agent) are associated with AP.
Pancreatic Cancer
Four studies explored this outcome
[16, 18, 19, 22]. For exenatide there was no
association [19, 22]. For liraglutide both studies
suggest no association for this outcome [16, 18].
Overall, these findings provide reassurance that
neither the class overall nor the individual
agents examined appear to be associated with
PC over longer-term exposure.
Thyroid Cancer
One study explored this outcome [14, 19],
which suggests no association for exenatide
exposure for this outcome (for TCs in general
and not MTC specifically). It is difficult to draw
conclusions from a single study and this out-
come should be investigated further.
Renal Outcomes
One study explored the association of exenatide
with ARF [21]. Exposure did not appear to be
associated with time-to-ARF and appears safe
from the renal perspective. None of the out-
comes trials explored renal events as a primary
outcome (and were not reported in EXSCEL),
although a secondary analysis of LEADER sug-
gests that liraglutide exposure caused a reduc-
tion in the renal composite outcome (new-
onset persistent microalbuminuria, persistent
doubling of the serum creatinine level, ESRD, or
death due to renal disease) driven mainly by a
reduction in persistent microalbuminuria
[3, 5, 42]. However, exenatide is renally excreted
and should not be used in those with pre-ex-
isting renal impairment [43].
Diabetic Retinopathy
One study explored GLP1RA class exposure on
DR and was associated with a neutral effect on
this outcome (except a transient increase in risk
at 6–12 months) [27]. It is difficult to draw
conclusions from a single study and this out-
come ought to be investigated further. In those
with pre-existing eye disease caution should be
employed and, in particular, slow titration
should be considered to avoid rapid correction
of hyperglycaemia which may precipitate DR.
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Breast Cancer
Two studies explored this outcome [17, 29].
One study showed no association with breast
cancer for the GLP1RA class overall, for exe-
natide and for liraglutide (except a transient
increased in risk at 3–4 years) [29]. The other
study showed no association for liraglutide [17].
These data appear to suggest that GLP1RA
agents are not associated with an increased risk
for this outcome.
Hypoglycaemia
Three studies explored this outcome
[20, 24, 31]. For the GLP1RA class and for exe-
natide, the studies showed no association of
exposure with hypoglycaemia (compared to
insulin). GLP1RAs alone do not appear to
increase the risk of hypoglycaemia, but may
increase hypoglycaemia risk when co-prescribed
with other drugs known to cause low blood
glucose [39]. Given that the studies identified
were compared directly to insulin use (and not
co-prescription with insulin), these data do not
shed light on this important question.
Strengths and Limitations
To our knowledge, this is the first systematic
review to assess population-based observational
studies looking at the effectiveness and safety of
GLP1RA agents in T2D. We searched a large
number of studies and involved a University of
Edinburgh informationist to use appropriate
search terms to ensure we captured the largest
possible number of studies. We present data
from many different countries and diverse
populations of people living with T2D and the
quality of the included papers is reported.
Importantly, some outcomes, particularly
pancreatic disease, were assessed by combining
GLP1RA and DPP4I exposure by assuming a
common ‘incretin’ pathway leading to these
pathologies (e.g. Singh et al. [44]). These stud-
ies, where it was not possible to discern an effect
estimate for a GLP1RA agent alone, were
prospectively excluded from this review
(Table S2).
A major challenge was the variety of com-
posite endpoints in the studies identified,
particularly for CVD, making direct compar-
isons difficult. While composite primary end-
points is useful for increasing the power of a
study to detect change (by increasing the events
counted towards the primary endpoint) it
would be helpful if future studies emulated the
composite outcomes reported in the cardiovas-
cular outcomes trials. This would be useful for
comparing identified studies to each other and
also to RCT data.
CVOTs have shown that liraglutide, subcu-
taneously administered semaglutide and
dulaglutide reduce MACE [2, 6, 7]. Given that
the last two agents have been licensed more
recently, we did not identify population-based
studies exploring these agents. It will be
important to assess these agents’ effects on CVD
in day-to-day clinical practice once sufficient
person-time exposure has accumulated to allow
for such analyses.
We deliberately excluded disproportionality
reporting ratio studies based on interrogating
adverse event reporting databases because of the
high risk of bias, especially once an adverse
event becomes known. However, gastroe-
sophageal reflux-like symptoms [45] and
intestinal obstruction [46] both emerged as
potential harms from these studies and should
be investigated further.
As with all observational data exploring
treatment effectiveness, the studies included
may be subject to unmeasured confounding
and bias, particularly measurement/misclassifi-
cation bias. Using population-based studies
reduces the effect of selection bias but observa-
tional pharmacoepidemiology is always subject
to confounding-by-indication, although most
of the included studies used modern methods of
controlling for this (e.g. propensity score
matching, PSM). It remains the case that despite
adequate study design and analysis methods,
the associations described might be entirely
explained away, or even reversed, by bias and
confounding, particularly unmeasured
confounding.
Notwithstanding considerable effort on our
part to identify eligible studies systematically
(including the manual searching of references),
it remains possible that we overlooked poten-
tially suitable studies and we omitted non-
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English language publications as a result of
resource issues; thus, our findings may be
affected by publication bias, which we could
not measure using a funnel plot because of
insufficient numbers of studies. Although the
search terms we employed should detect
observational studies conforming to the
Strengthening The Reporting of OBservational
studies in Epidemiology (STROBE) items on
publication title and abstract, studies not con-
forming would be missed (but non-conforming
could be considered a marker of poor quality at
any rate).
We did not use meta-analytic methods in
this review because of axiomatic breaches of the
methodology, including significant study
diversity and possible double counting of out-
come events.
CONCLUSIONS
This work provides broadly generalisable effec-
tiveness estimates in more heterogeneous pop-
ulations than those included in CVOTs. Our
study confirms that GLP1RAs, either as a class or
as individual agents, do not appear to be asso-
ciated with an increased risk of CV events and
are safe from this perspective. For liraglutide,
our review confirms and extends trial findings
that this agent appears to be associated with a
reduction in CV events of similar direction and
order of magnitude to the CVOT.
The included studies did not find evidence of
previously reported safety outcomes, although
some outcomes were only explored in a single
study (or a small number of studies). GLP1RAs
do not appear to be associated with pancreatic
pathology, TC, worse renal outcomes (in those
without baseline CKD), incident DR (in those
without baseline DR), incident breast cancer
and displayed a decreased or no association on
the risk of hypoglycaemia (when compared to
insulin/OAD respectively). Given the hetero-
geneity of the studies in terms of outcome def-
inition, population, confounding control and
analysis method, making generalised conclu-
sions about these data is challenging.
These data will be of use to people living
with T2D, their clinicians, medical regulators
and guideline-writing organisations and should
be updated as more data become available.
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